Quantcast
The Benefits Of Eating A High-Protein Breakfast Every Day

The Benefits Of Eating A High-Protein Breakfast Every Day

Brett Smith for redOrbit.com - Your Universe Online Nutritionists have long-advocated for starting the day with a complete breakfast and now a new study from the University of Missouri has found that a breakfast particularly high in protein can...

Latest Catecholamines Stories

2014-10-14 12:26:46

Sales of a Novel Antipsychotic and an Improved Rescue Therapy Will Contribute Approximately $1 Billion to the PD Market in 2023, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 14, 2014 /PRNewswire/ -- Decision Resources Group finds that the Parkinson's disease (PD) pharmacotherapy market will grow 5 percent annually from $2.3 billion in 2013 to $3.8 billion in 2023. This growth will be fueled by the launch of several emerging therapies--including new molecular...

2014-09-03 12:30:29

Continuous levodopa therapy with ND0612H has the potential to prevent or delay the need for surgical intervention in patients with severe stage Parkinson's disease REHOVOT, Israel, September 3, 2014 /PRNewswire/ -- NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that the first patients with severe Parkinson's disease have been enrolled and dosed in a Phase IIa trial of ND0612H. ND0612H is a...

2014-08-21 16:24:23

REHOVOT, Israel, August 21, 2014 /PRNewswire/ -- NeuroDerm [http://www.neuroderm.com ] Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it has signed definitive investment agreements for a $16 million financing round led by certain of its existing investors with the participation of new investors, including The Elias Group. The company plans to use the funding to further the clinical and regulatory...

2014-08-04 08:27:58

REHOVOT, Israel, August 4, 2014 /PRNewswire/ -- NeuroDerm [http://www.neuroderm.com ] Ltd. today announced that the European Medicines Agency (EMA) has deemed ND0612H, its product candidate offering continuous delivery of levodopa/carbidopa (LD/CD) treatment for advanced Parkinson's disease, eligible for a European Union marketing authorization application procedure ("centralized procedure"). According to EMA guidelines, the EMA can allow products for which the centralized...

2014-07-24 11:40:21

UCI News Flawed dopamine signaling linked to mass alteration of gene activity in prefrontal cortex Dysfunction in dopamine signaling profoundly changes the activity level of about 2,000 genes in the brain’s prefrontal cortex and may be an underlying cause of certain complex neuropsychiatric disorders, such as schizophrenia, according to UC Irvine scientists. This epigenetic alteration of gene activity in brain cells that receive this neurotransmitter showed for the first time that...

Parkinson's Enhances Creativity: Study
2014-07-15 03:26:50

Tel Aviv University New TAU study confirms creative energy in Parkinson's sufferers is greater than in healthy individuals Prof. Rivka Inzelberg of Tel Aviv University's Sackler Faculty of Medicine and the Sagol Neuroscience Center at Sheba Medical Center, Tel Hashomer, documented the exceptional creativity of Parkinson's patients two years ago in a review for Behavioral Neuroscience. Since then, she has conducted the first empirical study to verify a link between Parkinson's disease...

2014-06-18 16:26:35

NEW YORK, June 18, 2014 /PRNewswire-USNewswire/ -- With long-term use, the gold standard medication for Parkinson's disease, levodopa, can wear off before it's time for another dose, causing motor fluctuations called "off" episodes. Complicating treatment is that too much levodopa can cause debilitating side effects such as dyskinesia. Todd Sherer, PhD, CEO of The Michael J. Fox Foundation for Parkinson's Research talked to MJFF Contributing Editor Dave Iverson for a podcast on why...

2014-06-18 12:36:07

LONDON, June 18, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Parkinson's Disease: World Drug Industry and Market 2014-2024http://www.reportbuyer.com/pharma_healthcare/therapeutic/parkinson_s_disease_world_drug_industry_market_2014_2024.html Report DetailsTreating Parkinson's - how you find business trends, R&D, and revenue forecastsSee the future of Parkinson's drugs. For those treatments you can get new sales predictions, also exploring research...

2014-06-10 08:31:23

EMERYVILLE, Calif., June 10, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today presented data on the rater and subject training process utilized in the Phase 2/3 EASED safety and efficacy study of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a condition characterized by involuntary movements without purpose that can become severely disabling, rendering individuals with Parkinson's disease unable to perform routine daily tasks. In order to...

2014-06-09 16:25:26

EMERYVILLE, Calif., June 9, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced today that it has initiated a pivotal Phase 3 clinical study of ADS-5102 (amantadine HCl), a high-dose, controlled-release version of amantadine for the treatment of patients with Parkinson's disease who have developed levodopa-induced dyskinesia (LID). LID is a condition characterized by involuntary movements without purpose that can become severely disabling, rendering individuals...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.